Key result
TKIs-induced hypertension was associated with significantly longer progression-free survival (HR 0.59) and overall survival (HR 0.57) in patients with metastatic renal cell carcinoma.
Why the study?
Conflicting evidence exists regarding the effect of hypertension on the prognosis of metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
Does the development of TKIs-induced hypertension predict improved progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors?
Meta-Analysis (n=4,661)
Does the development of TKIs-induced hypertension predict improved progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors?
Hazard Ratio: 0.59 (95% CI 0.48–0.71)
p-value: p=<0.001
The development of hypertension during tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma is a strong clinical predictor of improved progression-free and overall survival.
No takes yet. Share an insight, caveat, or question.
Supports hypertension as on-treatment biomarker in mRCC; confirms association across TKIs but leaves open management implications.
Liu et al. (2019) conducted a meta-analysis in Metastatic renal cell carcinoma (mRCC) (n=4,661). TKIs-induced hypertension vs. Without TKIs-induced hypertension was evaluated on Progression-free survival (PFS) (HR 0.59, 95% CI 0.48-0.71, p=<0.001). TKIs-induced hypertension was associated with significantly longer progression-free survival (HR 0.59) and overall survival (HR 0.57) in patients with metastatic renal cell carcinoma.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: